Maladies hémorragiques congénitales : quel avenir pour les dérivés plasmatiques par rapport aux recombinants et aux produits sanguins labiles ?
| Autor: | J.-F. Schved |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
business.industry media_common.quotation_subject Biochemistry (medical) Clinical Biochemistry Hematology 030204 cardiovascular system & hematology Recombinant factor viii Hemorrhagic disorder 3. Good health law.invention 03 medical and health sciences Antihemophilic factors 0302 clinical medicine law 030220 oncology & carcinogenesis Immunology Recombinant DNA medicine business media_common Factor IX medicine.drug Recombinant factor IX |
| Zdroj: | Transfusion Clinique et Biologique. 22:85-89 |
| ISSN: | 1246-7820 |
| DOI: | 10.1016/j.tracli.2015.03.006 |
| Popis: | Until 1990, congenital hemorrhagic disorders were treated by plasma-derived concentrates. The first recombinant drug, recombinant factor VIII was available after this date and few years later recombinant factor IX could also be proposed to patients. The evolution of market share in France was different between these two drugs: while recombinant factor VIII took a large place in hemophilia A treatment (85%), plasma-derived factor IX represent 50% of the French market. In the next years, the arrival of long-acting antihemophilic factors may lead to the dramatically reduce the amount of plasma-derived antihemophilic factors used to treat hemophilia. For rare bleeding coagulation disorders, plasma-derived concentrates are still widely used, while they are the only concentrates available in most diseases. This situation is unlikely to evolve significantly in the next years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect